knowledge -WSS

knowledge

author：entertainment 2025-10-01 17:20:07 - browse：23373

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Beam Therapeutics to lay off 20% of its staff, re

entertainment

knowledge

WSS

Why health workers in Gaza are injured or die at high rates

GOP presidential candidates start declaring their loyalty

Senate committee scrutinizes Medicare Advantage brokers

Hospital price transparency does save money, advocate argues

White House drug shortages task force keeps mum with Congress

UnitedHealth’s board chair also owns a personal investment firm

knowledge

knowledge

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

STAT Summit: Biotech founders on deal

Heart attack and stroke risk calculators need revising

Hospital price transparency does save money, advocate argues

Cancer drug shortages should be causing more outrage

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare reduced heart disease by changing how it pays doctors

The high cost of giving birth even with insurance

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

leisure time

Beam Therapeutics to lay off 20% of its staff, re

How climate

FDA struggles to regulate food additives, sometimes for decades

The history of OxyContin, told through Purdue Pharma documents

FDA warns J&J's Abiomed: We will regulate your software

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

leisure time

entertainment

knowledge

hotspot